Canada markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.42+1.57 (+7.91%)
At close: 04:00PM EDT
21.42 0.00 (0.00%)
After hours: 05:00PM EDT
Sign in to post a message.
  • F
    Fghyujk Sdfghj
    A rational discussion ensued after what is known about Insmed, its revenues for this year, cash burn, trials etc. and the SP at the end of the year projection. Unlike those who push stock hype, solid price targets were given realizing that the average price target for Insmed this year by offering managers is $51.40 which is highly unlikely unless there is major news. None of the projections reached the $40 Lewis sold at last year.
  • T
    Terry
    The counter trend rally (Dow) is being played out from an oversold condition.
    Valuations overdone in last years rally so now its all about Insmeds revenues
    So these 2 charts are different so know your theatre. ^NBI has been a bear for months,( but see my post below on the triple bottom) The DOW just a month ago so... but they are almost always entwined. Russell 2000 peaked 18 months ago... The downtrend is obvious but a strong channel trade is possible
    I'll guess.... but watch that a few weeks of rally. perhaps right into Aug revenues which better be good. Contrary to companybs revenues have been weak overseas and far from the Fuds hundreds of millions in Japan in 2022
    The US as has been as expected and as informed Insmed investors realized US full market penetration was just a year after launch (Feb 21 EC)
    so Ill guess but know change is trading ... $25 into earnings call , fingers crossed
    Good Luck
    surfs up
  • t
    toostsie
    10 Stocks Under $30 to Buy Today According to Billionaire Steven Cohen. INSM
    Institutional Insmed holders 2.4M shares) owner POINT72 ASSET MANAGEMENT, L.P. "The company hired a new chief commercial officer in May 2022, with the intent to focus on a drug line for maximizing profits."
    Any Press is good press.
  • Q
    Quick
    Barrons article Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors Yahoo wont let the article or the link stick
    the jist is it could turn Big Pharma stocks from buy-and-stuff-under-the-mattress blue chips into riskier bets. At the same time, it may reinforce the long-term shift that has pulled Big Pharma’s focus toward expensive, specialized treatments and away from drugs for the most common causes of death in the U.S., such as heart disease and diabetes.
    Insmed in a sweet spot? 2 years away
  • J
    Joe Blow
    I have accepted the reality that INSM will do nothing until mid 2024 when the Phase3 brensocatib results are known. We know arikayce revenues. I wish I had sold this many times; LEWIS DID! and then turned around and got even lower priced options{ like free}. Posts here about the cash churning Institutional shorting are spot on.
  • J
    Jan
    Talking heads are all over the place a stronger FED response is on the table according to GS.
    Insmed is in one of the stocks in a defensive sector in a Bear market and is fully funded for at least a couple of years with money tightening.
  • Z
    Zorro
    One Investor Village multiple ID poster missing. One person a lot offraud
    Multiple IDs bohemian aka rick aka faust aka etc hasn't posted here either for 6 days.
  • T
    Terry
    Multi year pandemic low 3 years ago was $11.72,...... 2 years earlier in 2017 the low was $11.61, ...
    My $9.86 Buy with both fists in June 2016 . Look for a bounce from here. Insmed is trading technically not by investment. With any SP effective News a year or two out ,unless you trade and Joes post below shows volume is weak. My skepticism on Insmed is that this medical team is doing all the trialing. Seeds of Doubt!
  • r
    rufus
    thank LizCheney. A true Profile in Courage.
  • Q
    Quick
    Wall street believes= INSM Institutional Holdings Ownership Summary
    Institutional Ownership 108.05 %
    Total Shares Outstanding (millions) 120
    Total Value of Holdings (millions) $2,522
    Increased Positions 124 *********** 12,124,057
    Decreased Positions 89 **************6,388,281
  • J
    Jan
    What happens when you fail a Phase 3 trial. ATHIRA PHARMA, INC = down 65%+
    Realize Insmed has arikayce but the SP is weighted to brensocatib.
  • Y
    Yous
    Market closed tomorrow. Heavy read on the large hedge funds SELL position last week ( The Second Largest Ever) #$%$P just enters Bear market. 50% drop in last 3 ( exclude the fast 33% pushdown because of covid.Insmed is very close to failing that low Friday was short covering with Insmed , Getting tired since Insmed has been bear for almost a year.
  • P
    Predict
    Insmed shareholders have gotten used to this wash rinse repeat routine and the almost 9 % move ( now) is short covering. I agree the stock is captive to Institutional shorts and only deal news or better revenues will break us out of this slump. Weak 2qtr numbers and this year is lost. Have a nice 3 day holiday
  • Q
    Quick
    Short interest data out yesterday shows another 100k down but still at a high almost 10% of the float
    5/31/2022 10,908,425 1,247,804
    05/13/2022 11,007,166 1,727,226
    04/29/2022 11,295,780 921,806
  • O
    Ouch
    Deleted post ZACKS = "insmed-insm-expected-to-beat-earnings-estimates-can-the-stock-move-higher
    Insmed (INSM) Expected to Beat Earnings Estimates:
    according to Zacks Investment Research. Six analysts have issued estimates for Insmed’s earnings, with estimates ranging from $55.76 million to $61.62 million. Insmed posted sales of $45.37 million in the same quarter last year, which would indicate a positive year over year growth rate of 29.7%. The company is expected to announce its next earnings results on ERR Aug 1st.
  • t
    toostsie
    Anyone know the status of Zambon , the Italian pharma who recently completed A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa) ClinicalTrials.gov Identifier: CT03460704. Conducted in hundreds of sites in Europe.
  • F
    Fghyujk Sdfghj
    #$%$ at his second home BIO2022 learning all about Rancho Sante Fe and Insmed.
  • P
    Paul Thompson
    Weak market conditions means lowering of targets. This morning Goldman Sachs lowered their target from $56 down to $48. imo the first of many.
  • r
    rocky
    POST DELETED by bohemianclubman \rick" here it is.
    Quantitative tightening begins today with Jamie Dimon calling for a hurricane in the markets as money will be hard to come by, Credit card defaults and liquidity among corporations tight. Is Insmed prepared? Going to be a long hot summer. Hope they can produce better then expected number or all those $10 dollar posts may come true. Serious replies only No IVstuff
  • Y
    Yous
    New CCO just got another half a million worth of stock. These people throw around shares so easily I suspect this is how they pay direct officers. Yesterday Wise had to declare he owned 51,901 shares of Insmed to the SEC before being gifted another 21K of stock.
    Nice work if you can get it.
    Youssef